Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06012916 · ClinicalTrials.gov registry record
Brain Network Dynamics of Depression During Esketamine Treatment
A clinical trial of Depressive Disorder, Major, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT06012916 is a study of Depressive Disorder, Major that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 8 participants, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06012916, a study of Depressive Disorder, Major, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a monocentric, observational clinical trial investigating the effect of Esketamine on brain network activity and a belief updating task in people with depression. We investigate the immediate and the long-term effect (approx. 8 weeks) of Esketamine on EEG signals, pupillometry and belief updating and the relation of those effects on depressive symptomatology.
Conditions Studied
Interventions
- DRUG Esketamine nasal spray
Study Locations (1)
North Carolina
- Carolina Center for Neurostimulation - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-07-03 |
| Est. Completion | 2024-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06012916
The ClinicalTrials.gov registry entry for NCT06012916 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (97% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention - of which Esketamine nasal spray is the first listed.
NCT06012916 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06012916 about?
NCT06012916 is a clinical study titled "Brain Network Dynamics of Depression During Esketamine Treatment". This is a monocentric, observational clinical trial investigating the effect of Esketamine on brain network activity and a belief updating task in people with depression. We investigate the immediate and the long-term effect (approx. 8 weeks) of Esketamine on EEG signals, pupillometry and belief upd...
What is the current status of trial NCT06012916?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2023-07-03. Estimated completion is 2024-08-30.
What conditions does trial NCT06012916 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT06012916?
The interventions under investigation include: Esketamine nasal spray (DRUG).
Who is sponsoring clinical trial NCT06012916?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06012916 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
RECRUITING
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
RECRUITING · NA
-
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
RECRUITING · NA
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.